Machine learning predictions based on historical earnings data and price patterns
1-Day Prediction
+0.23%
$25.84
0% positive prob.
5-Day Prediction
-2.01%
$25.27
0% positive prob.
20-Day Prediction
-3.05%
$25.00
0% positive prob.
SEC 8-K filings with transcript text
Feb 3, 2026 · 100% conf.
1D
+0.23%
$25.84
Act: +4.46%
5D
-2.01%
$25.27
Act: +7.08%
20D
-3.05%
$25.00
Act: +3.12%
pfe-202602030000078003false00000780032026-02-032026-02-030000078003us-gaap:CommonStockMember2026-02-032026-02-030000078003pfe:NotesDue20271.000Member2026-02-032026-02-030000078003pfe:NotesDue20292.875Member2026-02-032026-02-030000078003pfe:NotesDue20323.250Member2026-02-032026-02-030000078003pfe:NotesDue20373.875Member2026-02-032026-02-030000078003pfe:NotesDue20454.250Member2026-02-032026-02-03
Washington, D.C. 20549
PURSUANT TO SECTION 13 OR 15(d) OF THE
Date of Report (Date of earliest event reported): February 3, 2026
(Exact name of registrant as specified in its charter)
Delaware1-361913-5315170 (State or other(Commission File(I.R.S. Employer jurisdiction ofNumber)Identification No.) incorporation)
66 Hudson Boulevard East10001-2192 New York, New York (Zip Code)
(Address of principal executive offices)
Registrant’s telephone number, including area code: (212) 733-2323
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2 (b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered Common Stock, $0.05 par valuePFENew York Stock Exchange 1.000% Notes due 2027PFE/27 New York Stock Exchange 2.875% Notes due 2029
New York Stock Exchange 3.250% Notes due 2032
New York Stock Exchange 3.875% Notes due 2037
New York Stock Exchange 4.250% Notes due 2045
New York Stock Exchange
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition
On February 3, 2026, Pfizer Inc. (“Pfizer”) issued a press release announcing its financial results for the fourth quarter of 2025. A copy of the press release is furnished herewith as Exhibit 99 and is incorporated by reference herein.
The information furnished pursuant to this “Item 2.02 - Results of Operations and Financial Condition”, including Exhibit 99, shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities of that section, and shall not be deemed to be incorporated by reference into any filing made by us under the Exchange Act or Securities Act of 1933, as amended, regardless of any general incorporation language in any such filing, except as shall be expressly set forth by specific reference in such filing.
Item 9.01 Financial Statements and Exhibits (d) Exhibits
Exhibit NumberExhibit Description
Exhibit 99 Press Release of Pfizer Inc. dated February 3, 2026, reporting Pfizer’s financial results for the fourth quarter of 2025.
104Cover Page Interactive Data File--the cover page XBRL tags are embedded within the Inline XBRL document.
Exhibit No.Description
99 Press Release of Pfizer Inc. dated February 3, 2026, reporting Pfizer’s financial results for the fourth quarter of 2025.
104Cover Page Interactive Data File--the cover page XBRL tags are embedded within the Inline XBRL document.
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
By:/s/ Margaret M. Madden Margaret M. Madden Senior Vice President and Corporate Secretary Chief Governance Counsel
Dated: February 3, 2026
Nov 4, 2025
pfe-202511040000078003false00000780032025-11-042025-11-040000078003us-gaap:CommonStockMember2025-11-042025-11-040000078003pfe:NotesDue20271.000Member2025-11-042025-11-040000078003pfe:NotesDue20292.875Member2025-11-042025-11-040000078003pfe:NotesDue20323.250Member2025-11-042025-11-040000078003pfe:NotesDue20373.875Member2025-11-042025-11-040000078003pfe:NotesDue20454.250Member2025-11-042025-11-04
Washington, D.C. 20549
PURSUANT TO SECTION 13 OR 15(d) OF THE
Date of Report (Date of earliest event reported): November 4, 2025
(Exact name of registrant as specified in its charter)
Delaware1-361913-5315170 (State or other(Commission File(I.R.S. Employer jurisdiction ofNumber)Identification No.) incorporation)
66 Hudson Boulevard East10001-2192 New York, New York (Zip Code)
(Address of principal executive offices)
Registrant’s telephone number, including area code: (212) 733-2323
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2 (b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered Common Stock, $0.05 par valuePFENew York Stock Exchange 1.000% Notes due 2027PFE/27 New York Stock Exchange 2.875% Notes due 2029
New York Stock Exchange 3.250% Notes due 2032
New York Stock Exchange 3.875% Notes due 2037
New York Stock Exchange 4.250% Notes due 2045
New York Stock Exchange
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition
On November 4, 2025, Pfizer Inc. (“Pfizer”) issued a press release announcing its financial results for the third quarter of 2025. A copy of the press release is furnished herewith as Exhibit 99 and is incorporated by reference herein.
The information furnished pursuant to this “Item 2.02 - Results of Operations and Financial Condition”, including Exhibit 99, shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities of that section, and shall not be deemed to be incorporated by reference into any filing made by us under the Exchange Act or Securities Act of 1933, as amended, regardless of any general incorporation language in any such filing, except as shall be expressly set forth by specific reference in such filing.
Item 9.01 Financial Statements and Exhibits (d) Exhibits
Exhibit NumberExhibit Description
Exhibit 99 Press Release of Pfizer Inc. dated November 4, 2025, reporting Pfizer’s financial results for the third quarter of 2025.
104Cover Page Interactive Data File--the cover page XBRL tags are embedded within the Inline XBRL document.
Exhibit No.Description
99 Press Release of Pfizer Inc. dated November 4, 2025, reporting Pfizer’s financial results for the third quarter of 2025.
104Cover Page Interactive Data File--the cover page XBRL tags are embedded within the Inline XBRL document.
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
By:/s/ Margaret M. Madden Margaret M. Madden Senior Vice President and Corporate Secretary Chief Governance Counsel
Dated: November 4, 2025
Aug 5, 2025
pfe-202508050000078003false00000780032025-08-052025-08-050000078003us-gaap:CommonStockMember2025-08-052025-08-050000078003pfe:NotesDue20271.000Member2025-08-052025-08-050000078003pfe:NotesDue20292.875Member2025-08-052025-08-050000078003pfe:NotesDue20323.250Member2025-08-052025-08-050000078003pfe:NotesDue20373.875Member2025-08-052025-08-050000078003pfe:NotesDue20454.250Member2025-08-052025-08-05
Washington, D.C. 20549
PURSUANT TO SECTION 13 OR 15(d) OF THE
Date of Report (Date of earliest event reported): August 5, 2025
(Exact name of registrant as specified in its charter)
Delaware1-361913-5315170 (State or other(Commission File(I.R.S. Employer jurisdiction ofNumber)Identification No.) incorporation)
66 Hudson Boulevard East10001-2192 New York, New York (Zip Code)
(Address of principal executive offices)
Registrant’s telephone number, including area code: (212) 733-2323
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2 (b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered Common Stock, $0.05 par valuePFENew York Stock Exchange 1.000% Notes due 2027PFE/27New York Stock Exchange 2.875% Notes due 2029
New York Stock Exchange 3.250% Notes due 2032
New York Stock Exchange 3.875% Notes due 2037
New York Stock Exchange 4.250% Notes due 2045
New York Stock Exchange
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition
On August 5, 2025, Pfizer Inc. (“Pfizer”) issued a press release announcing its financial results for the second quarter of 2025. A copy of the press release is furnished herewith as Exhibit 99 and is incorporated by reference herein.
The information furnished pursuant to this “Item 2.02 - Results of Operations and Financial Condition”, including Exhibit 99, shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities of that section, and shall not be deemed to be incorporated by reference into any filing made by us under the Exchange Act or Securities Act of 1933, as amended, regardless of any general incorporation language in any such filing, except as shall be expressly set forth by specific reference in such filing.
Item 9.01 Financial Statements and Exhibits (d) Exhibits
Exhibit NumberExhibit Description
Exhibit 99 Press Release of Pfizer Inc. dated August 5, 2025, reporting Pfizer’s financial results for the second quarter of 2025.
104Cover Page Interactive Data File--the cover page XBRL tags are embedded within the Inline XBRL document.
Exhibit No.Description
99 Press Release of Pfizer Inc. dated August 5, 2025, reporting Pfizer’s financial results for the second quarter of 2025.
104Cover Page Interactive Data File--the cover page XBRL tags are embedded within the Inline XBRL document.
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
By:/s/ Margaret M. Madden Margaret M. Madden Senior Vice President and Corporate Secretary Chief Governance Counsel
Dated: August 5, 2025
This page provides Pfizer Inc. (PFE) earnings call transcripts from SEC 8-K filings along with AI-powered predictions for post-earnings price movements. Our machine learning models analyze historical earnings data, pre-earnings price patterns, volume changes, and volatility to predict 1-day, 5-day, and 20-day returns after each earnings release.
Earnings transcripts are sourced directly from SEC EDGAR filings. Predictions are generated using gradient boosting models trained on PFE's historical earnings reactions. All predicted returns are shown as percentages, and predicted prices are calculated from the closing price at the time of prediction. Past performance does not guarantee future results.